Compare Hasbro, Inc. (HAS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs ResMed Inc. — how do they compare? Hasbro, Inc. trades at $92.69 (market cap $13.05B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and ResMed Inc. for 51 Days on average.
| HAS | RMD | |
|---|---|---|
Market Cap | $13.05B | $31.89B |
Volume | 1,207,655 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $277.88 |
52-Week Low | $70.95 | $182.82 |
Typical Hold Time | 97 Days | 51 Days |
Enterprise Value | $15.24B | $31.24B |
Dividend Yield | 3.03% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains positive with a $107.60 price target, representing 18.5% upside potential from current levels. Recent news highlights continued momentum in the Magic: The Gathering franchise and new product collaborations.
The outlook remains constructive with projected revenue growth to $5.0B in 2026 and net income recovery to $794M. Key risks include high debt levels at 59.09% debt-to-asset ratio and recent net income volatility. The stock offers value with reasonable P/E of 16.14x and strong institutional interest, though investors should monitor Q3 2026 earnings on October 20 for confirmation of the turnaround trajectory.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
